AbCellera reports Q3 2026 results, highlights ABCL635 Phase 2 and $200M raise

AbCellera announced its third quarter 2026 financial and operational results on November 9, 2026, covering the period ended September 30, 2026.

The company announced positive top-line Phase 2 clinical trial data for ABCL635 that demonstrated significant reductions in the frequency and severity of moderate and severe vasomotor symptoms, a favorable tolerability profile, and significant improvements in sleep and patient global impression of change.¹ AbCellera said it expects to initiate late-stage development for menopausal VMS in 2027.¹ The company is also expanding the indications for ABCL635 to include VMS caused by hormone suppression associated with breast and prostate cancer treatment, with clinical trials in these two populations expected to begin in 2027.¹

In a subsequent event, AbCellera reported top-line data for the Phase 1 clinical trial of ABCL575, an antibody drug candidate targeting OX40 ligand for atopic dermatitis and other autoimmune conditions, with the study meeting all endpoints and showing a favorable tolerability profile and a pharmacokinetic profile supporting an extended dosing interval.¹ Despite this, AbCellera currently does not plan to develop ABCL575 past Phase 1.¹

The company also advanced three new programs into IND-enabling activities: ABCL992, a next-generation half-life extended analog of ABCL635 for VMS; ABCL385, an oncology candidate for an undisclosed indication; and ABCL646, a potential first-in-class antagonist of an undisclosed ion channel target.¹

On financing, AbCellera completed a $200 million offering of common shares and pre-funded warrants.¹ As a result, the company said it has over $790 million in total cash balances and marketable securities, and over $100 million in available non-dilutive government funding, bringing total available liquidity to over $890 million to execute on its strategy.¹